FLECTOR (diclofenac epolamine) by IBSA Institut Biochimique is analgesic, anti-inflammatory, and antipyretic properties. First approved in 2007.
Drug data last refreshed 2h ago
FLECTOR is a topical diclofenac epolamine patch indicated for acute back strain and soft tissue injuries. It is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX-1 and COX-2) to reduce prostaglandin synthesis, thereby decreasing pain, inflammation, and fever. The transdermal system delivers diclofenac directly to affected tissues while minimizing systemic exposure.
With LOE approaching and only $2M in Part D spending across 3,437 claims, FLECTOR faces significant competitive pressure (30% intensity) and declining market relevance, limiting team expansion opportunities.
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of diclofenac, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries
Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain
Worked on FLECTOR at IBSA Institut Biochimique? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
FLECTOR shows zero linked job openings, indicating minimal active hiring and limited career growth potential within the brand team. Roles supporting this product are likely consolidated or transitioning to portfolio exit strategies.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo